Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.80
MACK's Cash to Debt is ranked higher than
59% of the 919 Companies
in the Global Biotechnology industry.

( Industry Median: 16.62 vs. MACK: 0.80 )
MACK' s 10-Year Cash to Debt Range
Min: 0.8   Max: No Debt
Current: 0.8

Equity to Asset -0.59
MACK's Equity to Asset is ranked lower than
52% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. MACK: -0.59 )
MACK' s 10-Year Equity to Asset Range
Min: -4.85   Max: 0.24
Current: -0.59

-4.85
0.24
F-Score: 2
Z-Score: -6.45
M-Score: -3.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -182.94
MACK's Operating margin (%) is ranked higher than
64% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. MACK: -182.94 )
MACK' s 10-Year Operating margin (%) Range
Min: -2220.11   Max: -189.58
Current: -182.94

-2220.11
-189.58
Net-margin (%) -213.20
MACK's Net-margin (%) is ranked higher than
63% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -69.75 vs. MACK: -213.20 )
MACK' s 10-Year Net-margin (%) Range
Min: -2284.59   Max: -186.58
Current: -213.2

-2284.59
-186.58
ROA (%) -72.29
MACK's ROA (%) is ranked higher than
56% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -21.69 vs. MACK: -72.29 )
MACK' s 10-Year ROA (%) Range
Min: -110.9   Max: -71.71
Current: -72.29

-110.9
-71.71
ROC (Joel Greenblatt) (%) -839.55
MACK's ROC (Joel Greenblatt) (%) is ranked higher than
65% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -217.20 vs. MACK: -839.55 )
MACK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1483.52   Max: -1183.68
Current: -839.55

-1483.52
-1183.68
» MACK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2012

MACK Guru Trades in Q3 2012

Steven Cohen 866,000 sh (New)
» More
Q4 2012

MACK Guru Trades in Q4 2012

Steven Cohen Sold Out
» More
Q1 2014

MACK Guru Trades in Q1 2014

Murray Stahl 12,000 sh (New)
» More
Q2 2014

MACK Guru Trades in Q2 2014

Paul Tudor Jones 13,622 sh (New)
Jim Simons 569,413 sh (New)
Murray Stahl 12,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with MACK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 13.25
MACK's P/S is ranked higher than
77% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 20.23 vs. MACK: 13.25 )
MACK' s 10-Year P/S Range
Min: 1.79   Max: 16.53
Current: 13.25

1.79
16.53
EV-to-EBIT -7.09
MACK's EV-to-EBIT is ranked higher than
66% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MACK: -7.09 )
MACK' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -7.09

Current Ratio 1.14
MACK's Current Ratio is ranked higher than
53% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 3.97 vs. MACK: 1.14 )
MACK' s 10-Year Current Ratio Range
Min: 1.14   Max: 4.51
Current: 1.14

1.14
4.51
Quick Ratio 1.14
MACK's Quick Ratio is ranked higher than
57% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 3.81 vs. MACK: 1.14 )
MACK' s 10-Year Quick Ratio Range
Min: 1.14   Max: 4.51
Current: 1.14

1.14
4.51

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.72
MACK's Price/Median PS Value is ranked higher than
74% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. MACK: 1.72 )
MACK' s 10-Year Price/Median PS Value Range
Min: 0.24   Max: 1.78
Current: 1.72

0.24
1.78

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:MP6.Germany
Merrimack Pharmaceuticals Inc is a biopharmaceutical company discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer.
» More Articles for MACK

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Nasdaq stocks posting largest percentage decreases Sep 22 2014
10 Stocks Trading Under $10 With Huge Upside Potential Sep 20 2014
Merrimack Pharmaceuticals to Present Clinical and Biomarker Data on Novel Antibody Therapeutics at... Sep 19 2014
5 Stocks Under $10 Soaring Higher Sep 12 2014
Market Has Not Yet Noticed Potential in Merrimack Pharmaceuticals (MACK); Have You? Sep 10 2014
Can Merrimack Pharmaceuticals (MACK) Run Higher on Strong Earnings Estimate Revisions? Sep 09 2014
Is Merrimack Pharmaceuticals (MACK) Stock a Solid Choice Right Now? Aug 28 2014
MERRIMACK PHARMACEUTICALS INC Financials Aug 19 2014
MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 11 2014
Q2 2014 Merrimack Pharmaceuticals Inc Earnings Release - Before Market Open Aug 11 2014
Merrimack Pharmaceuticals Announces Initiation of HERMIONE, a Randomized Trial of MM-302 in Patients... Aug 11 2014
Merrimack Pharmaceuticals Reports Second Quarter 2014 Financial Results Aug 11 2014
Merrimack Pharmaceuticals Announces Timing of Second Quarter 2014 Investor Conference Call Aug 04 2014
Is Now The Time To Buy Merrimack Pharmaceuticals? Jul 08 2014
MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jun 30 2014
Key Stocks With Insider Buying This Week Jun 28 2014
Merrimack Pharmaceuticals Presents Data From Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress... Jun 25 2014
5 Stocks With Big Insider Buying Jun 25 2014
Merrimack Falls Steeply as Sanofi Returns Oncology Drug Rights Jun 23 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK